These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. O'Brien JA, Patrick AR, Caro JJ. BMC Health Serv Res; 2003 Mar 21; 3(1):7. PubMed ID: 12659641 [Abstract] [Full Text] [Related]
7. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA; 1996 Nov 06; 276(17):1409-15. PubMed ID: 8892716 [Abstract] [Full Text] [Related]
8. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM, RENAAL Investigators. Pharmacoeconomics; 2006 Nov 06; 24(6):549-58. PubMed ID: 16761903 [Abstract] [Full Text] [Related]
13. How patients with diabetes perceive their risk for major complications. Meltzer D, Egleston B. Eff Clin Pract; 2000 Nov 06; 3(1):7-15. PubMed ID: 10788040 [Abstract] [Full Text] [Related]
14. The costs of treating long-term diabetic complications in a developing country: a study from India. Kumpatla S, Kothandan H, Tharkar S, Viswanathan V. J Assoc Physicians India; 2013 Feb 06; 61(2):102-9. PubMed ID: 24471248 [Abstract] [Full Text] [Related]
15. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Huang ES, Shook M, Jin L, Chin MH, Meltzer DO. Diabetes Care; 2006 Feb 06; 29(2):259-64. PubMed ID: 16443870 [Abstract] [Full Text] [Related]
16. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. CDC Diabetes Cost-effectiveness Group. JAMA; 2002 May 15; 287(19):2542-51. PubMed ID: 12020335 [Abstract] [Full Text] [Related]
17. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group. Rodby RA, Firth LM, Lewis EJ. Diabetes Care; 1996 Oct 15; 19(10):1051-61. PubMed ID: 8886549 [Abstract] [Full Text] [Related]
18. The economics of screening and treatment in type 2 diabetes mellitus. Raikou M, McGuire A. Pharmacoeconomics; 2003 Oct 15; 21(8):543-64. PubMed ID: 12751913 [Abstract] [Full Text] [Related]
19. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M. Diabetes Res Clin Pract; 2000 Jun 15; 48(3):201-10. PubMed ID: 10802159 [Abstract] [Full Text] [Related]
20. Direct medical costs of complications resulting from type 2 diabetes in the U.S. O'Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ. Diabetes Care; 1998 Jul 15; 21(7):1122-8. PubMed ID: 9653606 [Abstract] [Full Text] [Related] Page: [Next] [New Search]